Oral care compositions and methods

US9320696B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9320696-B2
Application numberUS-201414505496-A
CountryUS
Kind codeB2
Filing dateOct 2, 2014
Priority dateDec 21, 2009
Publication dateApr 26, 2016
Grant dateApr 26, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising a therapeutically effective amount of a MMP-13 inhibitor, and an orally acceptable carrier, wherein the MMP-13 inhibitor is 4-acetamidophenyl 2-isopropyl-5-methylcyclohexyl carbonate. 2. The composition of claim 1 , wherein the composition further comprises an MMP-13 inhibitor selected from the group consisting of cranberry extract non-dialyzable material, acetyl keto β-boswellic acid, resveratrol, and 2-isopropyl-5-methylcyclohexyl 2-hydroxyphenylcarbamate, and combinations thereof. 3. The composition of claim 2 , wherein the MMP-13 inhibitor comprises cranberry extract non-dialyzable material. 4. The composition of claim 2 , wherein the MMP-13 inhibitor comprises acetyl keto β-boswellic acid. 5. The composition of claim 2 , wherein the MMP-13 inhibitor comprises resveratrol. 6. The composition of claim 2 , wherein the MMP-13 inhibitor comprises 2-isopropyl-5-methylcyclohex 2-hydroxyphenylcarbamate. 7. The composition of claim 1 , wherein the composition is a dentifrice. 8. The composition of claim 7 , wherein the dentifrice is selected from the group consisting of: toothpaste; deep striped toothpaste; surface striped toothpaste; multi-layered toothpaste; a gel surrounding toothpaste; powder; beads; mouthwash; mouth rinses; lozenge; dental gel; a periodontal gel; a liquid suitable for painting a dental surface; a chewing gum; a dissolvable, partially dissolvable or non-dissolvable film or strip; a wafer; a wipe or towelette; an implant; a foam; a troche; a dental floss, liquid formulated for oral application in a small portable bottle; liquid formulated for oral application in a small portable drop-generating bottle; a soft pliable tablet; or a combination of two or more thereof.

Assignees

Inventors

Classifications

  • Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title

  • for bone diseases, e.g. rachitism, Paget's disease · CPC title

  • of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title

  • A61K31/19Primary

    Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

  • of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9320696B2 cover?
Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.
Who is the assignee on this patent?
Colgate Palmolive Co
What technology area does this patent fall under?
Primary CPC classification A61K31/19. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).